Ignite Creation Date:
2025-12-24 @ 2:31 PM
Ignite Modification Date:
2025-12-25 @ 7:15 PM
Study NCT ID:
NCT05487859
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-02-21
First Post:
2022-08-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Acarbose in Combination with Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
Sponsor:
University of Alabama at Birmingham
Organization:
Study Overview
Official Title:
A Pilot Study of the Immunomodulatory Agent Acarbose in Combination with Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety and tolerability of acarbose in combination of immunotherapy based standard of care therapy in advanced renal cell carcinoma patients.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: